Recent 8-K filings for ASMB

• May 07, 2026 23:59 UTC earnings materiality 0.55 neutral item 2.02item 9.01

  Q1 net loss $9.1M ($0.54/sh); cash $226.6M; HPI opt-in decision pending mid-2026

  Net loss $9.1M ($0.54/share) vs $8.8M ($1.17/share) in Q1 2025; cash $226.6M at quarter end.

• Mar 30, 2026 23:59 UTC other_material materiality 0.25 neutral item 5.02item 9.01

  Assembly Biosciences adopts 2026 bonus plan; raises CEO bonus target to 65%

  Compensation Committee approved 2026 Corporate Bonus Plan effective Jan 1, 2026 with corporate and individual performance objectives.

• Mar 19, 2026 23:59 UTC earnings materiality 0.80 positive item 2.02item 9.01

  Assembly Biosciences reports 2025 revenue of $72.3M; net loss narrows; licenses HPI program to Gilead

  Revenue from Gilead collaboration was $72.3M in 2025 (vs $28.5M in 2024); net loss per share $0.55 (vs $6.69).

• Dec 08, 2025 23:59 UTC other_material materiality 0.80 positive item 7.01item 8.01item 9.01

  Assembly Bio reports Phase 1b data: ABI-1179 98% HSV-2 shedding reduction, ABI-5366 monthly 76%

  ABI-1179 50 mg weekly: 98% HSV-2 shedding reduction (p<0.01), exceeds 80-85% target; 91% lesion reduction (p<0.01).

• Nov 10, 2025 23:59 UTC earnings materiality 0.70 positive item 2.02item 9.01

  Assembly Biosciences Q3 net loss $9.2M; cash $232.6M; positive Phase 1b data for ABI-5366

  Net loss of $9.2M ($0.72 per share) vs $9.6M loss in Q3 2024; revenue from Gilead collaboration $10.8M.

• Aug 11, 2025 23:59 UTC other_material materiality 0.70 neutral item 1.01item 3.02item 8.01item 9.01

  Assembly Bio prices $175M equity financing; net proceeds ~$167M

  Underwritten offering: 5.6M shares + 1.04M pre-funded warrants at $19.60/unit; net ~$122M.

• Aug 08, 2025 23:59 UTC other_material materiality 0.75 positive item 7.01item 8.01item 9.01

  Assembly Bio reports 94% reduction in HSV-2 shedding with ABI-5366 350mg weekly in Phase 1b

  94% reduction in HSV-2 shedding rate (p<0.01) for 350mg weekly dose vs placebo over 29-day evaluation.

• Aug 06, 2025 23:59 UTC earnings materiality 0.75 neutral item 2.02item 8.01item 9.01

  Assembly Bio reports Q2 net loss $10.2M; ABI-6250 shows 4-day half-life supporting once-daily dosing

  Net loss $10.2M ($1.33/share) vs $11.2M ($1.98/share) in Q2 2024; revenue from Gilead collaboration $9.6M.

• Jun 25, 2025 23:59 UTC other_material materiality 0.65 positive item 8.01item 9.01

  Assembly Bio reports positive Phase 1b topline results for ABI-4334 in chronic HBV; Gilead opt-in triggered

  Mean HBV DNA decline of 3.2 log10 IU/mL over 28 days in 400 mg cohort (2.9 logs in 150 mg cohort).

• Jun 09, 2025 23:59 UTC leadership materiality 0.55 neutral item 5.02item 5.07item 9.01

  Assembly Biosciences appoints new CFO; shareholders approve stock plan share increases

  Jeanette M. Bjorkquist appointed principal financial officer effective June 5, 2025; Jason A. Okazaki remains CEO.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event other_material

5 positive 0 negative 5 neutral

source · ASMB on sec.gov